uniQure price target lowered to $25 from $28 at Leerink

Leerink lowered the firm’s price target on uniQure to $25 from $28 and keeps an Outperform rating on the shares following quarterly results. The firm notes focus remains on AMT-130 in Huntington’s disease following a positive update in December 2023 where uniQure reported additional data for patients treated in the U.S. and EU studies with 18 months of follow-up in the high-dose group and 30 months of follow-up in the low-dose group.